Regeneron Pharmaceuticals, Inc. (REGN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Regeneron Pharmaceuticals reported revenue of $14.34B, up 1.0% from $14.20B the year before. Net income was $4.50B (a 31.4% net margin), or $41.48 per diluted share. Gross margin was 24.9% and operating margin was 24.9%. Operating activities generated $4.98B of cash, leaving $4.08B of free cash flow. At fiscal year end, Regeneron Pharmaceuticals held $40.56B in total assets against $9.30B in total liabilities, including $3.12B of cash and equivalents.
Open the full interactive Regeneron Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Regeneron Pharmaceuticals Key Stats
| Share Price | $753.12 |
|---|---|
| Market Cap | $79.83B |
| P/E Ratio | 18.2 |
| Dividend Yield | 0.47% |
| Revenue YoY Growth | +1.0% |
| 52-Week Range | $554.88 – $852.03 |
| Shares Outstanding | 102.8 million (basic, 2026 Q2) |
Regeneron Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.50B | $16.07B | $12.17B | $13.12B | $14.20B | $14.34B |
| Cost of Goods Sold | $4.92B | $7.12B | $7.43B | $9.07B | $10.21B | $10.77B |
| Gross Profit | $3.58B | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B |
| Operating Income | $3.58B | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B |
| Pre-Tax Income | $3.81B | $9.33B | $4.86B | $4.20B | $4.78B | $5.23B |
| Income Tax | $297.2M | $1.25B | $520.4M | $245.7M | $367.3M | $725.8M |
| Net Income | $3.51B | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| Diluted EPS | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
Regeneron Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.75B | $3.88B | $3.61B | $4.29B |
| Net Income | $1.46B | $844.6M | $727.2M | $1.30B |
| Diluted EPS | $13.62 | $7.78 | $6.75 | $12.23 |
Regeneron Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.19B | $2.89B | $3.11B | $2.73B | $2.49B | $3.12B |
| Current Assets | $9.78B | $14.01B | $15.88B | $19.48B | $18.66B | $18.02B |
| Total Assets | $17.16B | $25.43B | $29.21B | $33.08B | $37.76B | $40.56B |
| Current Liabilities | $2.70B | $3.93B | $3.14B | $3.42B | $3.94B | $4.37B |
| Total Long-Term Debt | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $1.99B |
| Total Liabilities | $6.14B | $6.67B | $6.55B | $7.11B | $8.41B | $9.30B |
| Shareholders' Equity | $11.03B | $18.77B | $22.66B | $25.97B | $29.35B | $31.26B |
Regeneron Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $2.62B | $7.08B | $5.01B | $4.59B | $4.42B | $4.98B |
| Cash From Investing | -$70.6M | -$5.38B | -$3.78B | -$3.19B | -$2.47B | -$629.1M |
| Cash From Financing | -$1.97B | -$1.01B | -$1.01B | -$1.79B | -$2.20B | -$3.72B |
| Free Cash Flow | $2.00B | $6.53B | $4.42B | $3.88B | $3.66B | $4.08B |
| Dividends Paid | — | — | — | — | — | $370.3M |
Figures from Regeneron Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Regeneron Pharmaceuticals financials page for every line item.
Regeneron Pharmaceuticals Company Profile
| Ticker | REGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Tarrytown, New York |
| Incorporated in | New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000872589 |
Frequently Asked Questions
What was Regeneron Pharmaceuticals' revenue in fiscal 2025?
Regeneron Pharmaceuticals (REGN) reported revenue of $14.34B for fiscal 2025.
What is Regeneron Pharmaceuticals' annual revenue history?
Regeneron Pharmaceuticals' annual revenue by fiscal year: 2020: $8.50B; 2021: $16.07B; 2022: $12.17B; 2023: $13.12B; 2024: $14.20B; 2025: $14.34B.
What was Regeneron Pharmaceuticals' net income in fiscal 2025?
Regeneron Pharmaceuticals reported net income of $4.50B for fiscal 2025.
What was Regeneron Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Regeneron Pharmaceuticals' diluted EPS was $41.48 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Regeneron Pharmaceuticals generate in fiscal 2025?
Regeneron Pharmaceuticals generated $4.08B of free cash flow in fiscal 2025.
What was Regeneron Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Regeneron Pharmaceuticals reported revenue of $4.29B.
How much debt does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals reported $1.99B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals reported a weighted average of 102.8 million basic shares outstanding in 2026 Q2.
What is Regeneron Pharmaceuticals' market cap?
Based on its latest closing price, Regeneron Pharmaceuticals (REGN) has a market capitalization of about $79.83B.
When does Regeneron Pharmaceuticals' fiscal year end?
Regeneron Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Regeneron Pharmaceuticals headquartered?
Regeneron Pharmaceuticals lists its business address in Tarrytown, New York in its SEC filings.